News | Chronic Total Occlusion (CTO) | November 02, 2017

Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI

Boston Scientific catheter yields similar crossing time, success and complication rates compared to wire escalation

Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI

November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and there is debate about the optimal initial crossing strategy during the procedure. Researchers randomized 246 patients undergoing coronary CTO intervention to upfront use of the CrossBoss catheter (N=122) or wire escalation (N=124) at 11 U.S. centers. Overall technical and procedural success rates were high and similar between the two groups. The primary efficacy endpoint, crossing time, was similar: 56 (interquartile range: 33, 93) minutes in the CrossBoss and 66 (36, 105) minutes in the wire escalation group (P=0.323), as was the incidence of procedural major adverse cardiovascular events (3.28 percent vs. 4.03 percent, P= 1.000). In the CrossBoss-first strategy, the first crossing technique was more likely to be antegrade dissection/re-entry (77 percent), compared with the wire escalation strategy, which was successful as the initial strategy 98 percent of the time among patients randomized to that study arm.

Trial results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 annual conference, Oct. 29-Nov. 2 in Denver.

“The CrossBoss First trial is the first randomized-controlled trial designed to compare two commonly utilized crossing techniques as the initial CTO crossing strategy,” said Emmanouil S. Brilakis, M.D., of the Minneapolis Heart Institute. “Compared with a primary wire escalation strategy, upfront use of the CrossBoss catheter for crossing CTOs was associated with similar crossing time, similar success and complication rates, and similar equipment utilization and cost. In a post hoc analysis upfront use of the CrossBoss catheter was associated with shorter crossing time in patient with in-stent CTOs. Use of antegrade dissection/re-entry was the final successful strategy in 22 percent of the wire escalation group patients.”

The CrossBoss First study was funded by Boston Scientific. Brilakis reported consulting/speaker honoraria from Abbott Vascular, Amgen, Asahi, CSI, Elsevier, GE Healthcare and Medicure. He also disclosed research support from Boston Scientific and Osprey, and that his spouse is an employee of Medtronic.

Read about other TCT 2017 late-breaking clinical trial presentations.

For more information: www.tctconference.com

Related CTO Content

VIDEO: Treating Chronic Total Occlusions

VIDEO: New Technology to Treat Chronic Total Occlusions (CTOs)

When to Consider Revascularization of Coronary Chronic Total Occlusions

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...